{
    "ticker": "PGEN",
    "name": "Pgen, Inc.",
    "description": "Pgen, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of cancer and other serious diseases. Founded in 2015, the company is dedicated to advancing the field of gene therapy and immunotherapy through its proprietary technologies and platforms. Pgen's lead product candidates are designed to harness the power of the immune system to target and destroy cancer cells while minimizing damage to healthy tissue. The company employs cutting-edge genetic engineering techniques to create personalized and off-the-shelf treatments, aiming to improve patient outcomes and enhance the quality of life for individuals battling cancer. Pgen is committed to conducting rigorous clinical trials to validate the safety and efficacy of its therapies, with the goal of bringing new treatment options to market. With a strong focus on research and development, Pgen collaborates with leading academic institutions and industry partners to accelerate the development of its product pipeline and expand its therapeutic offerings. The company's mission is to revolutionize cancer care through science and innovation, ultimately contributing to a future where cancer is more effectively managed and treated.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2015",
    "website": "https://www.pgen.com",
    "ceo": "Dr. A. John B. D. Smith",
    "social_media": {
        "twitter": "https://twitter.com/PgenInc",
        "linkedin": "https://www.linkedin.com/company/pgen-inc/"
    },
    "investor_relations": "https://ir.pgen.com",
    "key_executives": [
        {
            "name": "Dr. A. John B. D. Smith",
            "position": "CEO"
        },
        {
            "name": "Jane Doe",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "PGEN-101",
                "PGEN-102"
            ]
        },
        {
            "category": "Immunotherapy",
            "products": [
                "PGEN-201"
            ]
        }
    ],
    "seo": {
        "meta_title": "Pgen, Inc. | Innovating Cancer Therapies",
        "meta_description": "Explore Pgen, Inc., a biotechnology company focused on developing innovative gene therapies and immunotherapies for cancer treatment.",
        "keywords": [
            "Pgen",
            "Biotechnology",
            "Cancer Treatment",
            "Gene Therapy",
            "Immunotherapy"
        ]
    },
    "faq": [
        {
            "question": "What is Pgen known for?",
            "answer": "Pgen is known for developing innovative gene therapies and immunotherapies for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Pgen?",
            "answer": "Dr. A. John B. D. Smith is the CEO of Pgen, Inc."
        },
        {
            "question": "Where is Pgen headquartered?",
            "answer": "Pgen is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Pgen's main products?",
            "answer": "Pgen's main products include PGEN-101, PGEN-102, and PGEN-201."
        },
        {
            "question": "When was Pgen founded?",
            "answer": "Pgen was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}